133 related articles for article (PubMed ID: 33180662)
21. [Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast].
Gao BB; Zheng Q; Yu L; Luo DJ; Nie X; Xu X
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):843-849. PubMed ID: 36097900
[No Abstract] [Full Text] [Related]
22. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
[TBL] [Abstract][Full Text] [Related]
23. [Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping].
Gao LX; Liu G; Li L; Lin HY; Jin H; Cheng J; Jin ML; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):604-9. PubMed ID: 22177244
[TBL] [Abstract][Full Text] [Related]
24. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
25. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
[TBL] [Abstract][Full Text] [Related]
27. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
28. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
29. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
30. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
31. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam.
Dang Cong T; Nguyen Thanh T; Nguyen Phan QA; Hoang Thi AP; Nguyen Tran BS; Nguyen Vu QH
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1135-1142. PubMed ID: 32334482
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
33. Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.
Miyashita M; Gonda K; Tada H; Watanabe M; Kitamura N; Kamei T; Sasano H; Ishida T; Ohuchi N
Cancer Med; 2016 Oct; 5(10):2813-2824. PubMed ID: 27666577
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
35. [Pathologic diagnosis and differential diagnosis of low-grade adenosquamous carcinoma of breast and syringomatous adenoma of nipple].
Li J; Yang GZ; Jin H; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):301-4. PubMed ID: 22883667
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
[TBL] [Abstract][Full Text] [Related]
37. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
38. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma.
Guo S; Wang Y; Rohr J; Shang L; Ma J
J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702
[TBL] [Abstract][Full Text] [Related]
39. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
[TBL] [Abstract][Full Text] [Related]
40. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
